This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.

Inclusion criteria:

• Must have completed the Open-Label Phase of protocol LAM20006 or meet criteria for LAMICTAL naive subjects as follows:
• A confident diagnosis of epilepsy.
• 4 or more partial seizures per month.
• current treatment with 1 or 2 anti-epileptic drugs.

Exclusion criteria:

• Has seizures not related to epilepsy.
• Has a surgically implanted and functioning vagal nerve stimulator.
• Has previously been treated with lamotrigine.
• Is currently taking felbamate, ACTH (adrenocorticotrophic hormone) or is on the ketogenic diet.
• Use of experimental medication within 30 days of enrollment.

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.